{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:48:07Z","timestamp":1787852887456,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.03.088","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T20:29:20Z","timestamp":1428784160000},"page":"4238-4246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate"],"prefix":"10.1016","volume":"33","author":[{"given":"Diego","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Kratje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Etcheverrigaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vaccine.2015.03.088_bib0250","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0255","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.copbio.2013.02.008","article-title":"Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development","volume":"24","author":"Rodr\u00edguez-Limas","year":"2013","journal-title":"Curr Opin Biotechnol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.088_bib0260","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport for immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Method"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.copbio.2007.10.013","article-title":"Virus-like particles\u2014universal molecular toolboxes","volume":"18","author":"Ludwig","year":"2007","journal-title":"Curr Opin Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.088_bib0275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1128\/CMR.00005-07","article-title":"Curr Stat of Vet Vaccines","volume":"20","author":"Meeusen","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2011.02.006","article-title":"Current strategies for subunit and genetic viral veterinary vaccine development","volume":"157","author":"Brun","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vetimm.2012.04.026","article-title":"Virus-like particles: the new frontier of vaccines for animal viral infections","volume":"148","author":"Crisci","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.088_bib0290","first-page":"553","article-title":"Virus-like particles: potential veterinary vaccine immunogens","volume":"93","author":"Liu","year":"2011","journal-title":"Res Vet Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.088_bib0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cimid.2013.02.002","article-title":"Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design","volume":"36","author":"Liu","year":"2013","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0300","first-page":"425","article-title":"Rabies vaccines WHO position paper","volume":"49","author":"World Health Organization","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0305","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.vaccine.2013.12.031","article-title":"Rabies: underused vaccines, unnecessary deaths","volume":"32","author":"Dodet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0310","doi-asserted-by":"crossref","unstructured":"Bourhy H, Dautry-Varsat A, Hotez PJ, Salomon J. Rabies, still neglected after 125 years of vaccination. PLoS Negl Trop Dis 4(11):e839.","DOI":"10.1371\/journal.pntd.0000839"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0315","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.antiviral.2013.03.011","article-title":"Eliminating canine rabies, the principal source of human infection: what will it take?","volume":"98","author":"Meslin","year":"2013","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.088_bib0320","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.antiviral.2013.03.004","article-title":"Potential economic benefits of eliminating canine rabies","volume":"98","author":"Shwiff","year":"2013","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.vaccine.2015.03.088_bib0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/JVI.7.2.241-249.1971","article-title":"Structural proteins of rabies virus","volume":"7","author":"Sokol","year":"1971","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0330","first-page":"601","article-title":"Rabies","volume":"123","author":"Jackson","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1099\/0022-1317-68-4-1115","article-title":"T cell clones directed to rabies virus: isolation and some of their properties","volume":"68","author":"Cho","year":"1987","journal-title":"J Gen Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.088_bib0340","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.62.9.3128-3134.1988","article-title":"Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients","volume":"62","author":"Celis","year":"1988","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.088_bib0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0042-6822(92)90465-2","article-title":"Rabies virus glycoprotein is a trimer","volume":"187","author":"Gaudin","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0350","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-387040-7.00002-0","article-title":"Rabies virus assembly and budding","volume":"79","author":"Okumura","year":"2011","journal-title":"Adv Virus Res"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.088_bib0355","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1371\/journal.pntd.0000515","article-title":"Novel vaccines to human rabies","volume":"3","author":"Ertl","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0360","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2012.04592.x","article-title":"Developments in rabies vaccines","volume":"169","author":"Hicks","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0365","article-title":"Transient expression of rabies virus glycoprotein (RVGP) in Drosophila melanogaster Schneider 2 (S2) cells","author":"Pati\u00f1o","year":"2014","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0370","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1099\/0022-1317-72-2-359","article-title":"Stable expression of rabies virus glycoprotein in Chinese hamster ovary cells","volume":"72","author":"Burger","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0375","first-page":"594","article-title":"Expression of rabies virus glycoprotein gene into eukaryotic system and determination of potential T-cell epitopes","volume":"49","author":"Tomar","year":"2011","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0380","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00299-009-0782-3","article-title":"High level expression of a functionally active cholera toxin B: rabies glycoprotein fusion protein in tobacco seeds","volume":"28","author":"Tiwari","year":"2009","journal-title":"Plant Cell Rep"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.06.058","article-title":"A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice","author":"Koraka","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.088_bib0390","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.vaccine.2011.10.095","article-title":"Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3)","volume":"30","author":"Shen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0395","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.biologicals.2010.06.001","article-title":"Co-expression of double or triple copies of the rabies virus glycoprotein gene using a \u2018self-cleaving\u2019 2A peptide-based replication-defective human adenovirus serotype 5 vector","volume":"38","author":"Tan","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0400","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jbiotec.2008.12.009","article-title":"High-level expression of rabies virus glycoprotein with the RNA-based Semliki Forest Virus expression vector","volume":"139","author":"Rim Benmaamara","year":"2009","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0405","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1016\/j.vaccine.2009.09.033","article-title":"Poxvirus-vectored vaccines for rabies\u2014a review","volume":"27","author":"Weyera","year":"2009","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2015.03.088_bib0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vetmic.2008.10.030","article-title":"Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein","volume":"136","author":"Saxena","year":"2009","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0415","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.vaccine.2009.01.128","article-title":"Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge","volume":"27","author":"Kaur","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0420","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.vaccine.2014.02.031","article-title":"Rabies virus-like particles expressed in HEK293 cells","volume":"32","author":"Fontana","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0425","first-page":"284","article-title":"Violet d\u2019aniline","volume":"1","author":"Berthelot","year":"1859","journal-title":"Repert Chim Appl"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0430","series-title":"Laboratory techniques in rabies","first-page":"360","article-title":"The NIH test for potency","author":"Wilbur","year":"1996"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0435","series-title":"Laboratory techniques in rabies","first-page":"314","article-title":"Cell culture vaccines for veterinary use","author":"Reculard","year":"1996"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0440","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","article-title":"Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison","volume":"89","author":"Wright","year":"2008","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.03.088_bib0445","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1753-6561-5-S8-P7","article-title":"A strategy to obtain recombinant cell lines with high expression levels. Lentiviral vector-mediated transgenesis","volume":"5","author":"Prieto","year":"2011","journal-title":"BMC Proc"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0450","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0455","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2015.03.088_bib0460","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/erv.11.37","article-title":"Virus-like particles: innate immune stimulators","volume":"10","author":"Raghunandan","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2015.03.088_bib0465","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1371\/journal.pntd.0000595","article-title":"Rabies-specific antibodies: measuring surrogates of protection against a fatal disease","volume":"4","author":"Moore","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0470","first-page":"982","article-title":"WHO expert consultation on rabies. Second report","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0475","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2012.03.007","article-title":"The role of vaccination in rabies prevention","volume":"2","author":"Briggs","year":"2012","journal-title":"Curr Opin Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.03.088_bib0480","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/eji.201142064","article-title":"Virus-like particles induce robust T helper immune responses","volume":"42","author":"Braun","year":"2012","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.03.088_bib0485","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.088_bib0490","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0966-842X(93)90035-P","article-title":"Antibody-mediated clearance of viruses from the mammalian central nervous system","volume":"1","author":"Dietzschold","year":"1993","journal-title":"Trends Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:04:30Z","timestamp":1598904270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":49,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15004181"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}